No quarterly revenue total was found in Tyra Biosciences, Inc.'s SEC filings.
Tyra Biosciences, Inc. (TYRA) files with the SEC under industry code 2834, Pharmaceutical Preparations. Free cash flow was -$31.1 million. As of Jun 30, 2026 it held $353.9 million in cash and investments and $5.6 million in total debt.
Revenue
—
Net income
$-45.56M
-62.1% vs year-ago quarter
Operating cash flow
$-31.08M
-31.2% vs year-ago quarter
Free cash flow
$-31.14M
-31.3% vs year-ago quarter
EPS
$-0.69
-46.8% vs year-ago quarter
Dividend per share
None
Shares outstanding
59.68M
+12.0% vs year-ago quarter
Net cash
$348.36M
Q2 FY2026
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- TYRA (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Carlsbad, CA
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1863127
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
Q2 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Operating income | -$49.0M | -$42.0M | -$36.5M | -$32.9M | -$31.5M |
| Net income | -$45.6M | -$39.3M | -$33.8M | -$29.9M | -$28.1M |
| Diluted EPS | -$0.69 | -$0.64 | -$0.57 | -$0.50 | -$0.47 |
| Operating cash flow | -$31.1M | -$32.6M | -$23.6M | -$22.4M | -$23.7M |
| Free cash flow | -$31.1M | -$32.7M | -$23.7M | -$22.4M | -$23.7M |
| Total assets | $383.4M | $412.0M | $282.6M | $301.9M | $321.5M |
| Total liabilities | $29.7M | $24.5M | $23.4M | $21.3M | $19.4M |
| Stockholders' equity | $353.7M | $387.6M | $259.2M | $280.5M | $302.1M |
| Cash and investments | $353.9M | $383.5M | $256.0M | $274.9M | $296.3M |
| Total debt | $5.6M | $5.7M | $5.8M | $5.9M | $6.0M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Other events
|
Sep 15, 2026 | Sep 14, 2026 |
| 8-K |
Current report
Other events
|
Sep 9, 2026 | Sep 9, 2026 |
| 10-Q | Quarterly report | Aug 4, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 4, 2026 | Aug 4, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Jun 2, 2026 | May 28, 2026 |
| 10-Q | Quarterly report | May 13, 2026 | Mar 31, 2026 |
All 426 Tyra Biosciences, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.